Imuran (Azathioprine)

Azathioprine is converted to 6‑mercaptopurine, which blocks purine synthesis needed for DNA replication. This limits the proliferation of T and B lymphocytes, reducing the immune response that contributes to graft rejection and autoimmune inflammation.

The appropriate dose of Imuran is individualized by a healthcare professional based on the specific indication, patient weight, and clinical response. Prescribers determine the exact regimen and adjust it according to therapeutic monitoring.

Azathioprine crosses the placenta and is excreted in breast milk, so its safety in pregnancy and lactation is not fully established. Use is generally reserved for situations where the potential benefit outweighs the risk, and only under close medical supervision.

To request Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Compared with drugs like mycophenolate mofetil or cyclosporine, azathioprine offers a different metabolic pathway and may have a more favorable side‑effect profile for some patients, but individual response varies. Choice of therapy depends on the clinical scenario, tolerance, and physician judgment.

Imuran should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Imuran is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily or divided doses—depends on the prescribing clinician’s instructions.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, and increased susceptibility to serious infections. Patients should be monitored regularly for blood count changes, liver function abnormalities, and signs of infection.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with severe bone‑marrow failure, active infections, or significant liver disease. It should also be used with caution in individuals with TPMT deficiency.